Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents

被引：91

作者：

Aragon-Ching, Jeanny B. ^{[1
]}

Ning, Yang-Min

Chen, Clara C. ^{[2
]}

Latham, Lea

Guadagnini, Jean-Pierre ^{[3
]}

Gulley, James L.

Arlen, Philip M.

Wright, John J. ^{[4
]}

Parnes, Howard ^{[5
]}

Figg, William D. ^{[6
]}

Dahut, William L.

机构：

[1] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA

[2] NIH, Dept Nucl Med, Ctr Clin, Bethesda, MD USA

[3] Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD USA

[4] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA

[5] NCI, Canc Prevent Div, Bethesda, MD 20892 USA

[6] NCI, Mol Pharmacol Sect, Bethesda, MD 20892 USA

来源：

CANCER INVESTIGATION | 2009年 / 27卷 / 02期

基金：

美国国家卫生研究院;

关键词：

Osteonecrosis of the jaw; Bisphosphonates; Anti-angiogenesis; Chemotherapy; Prostate pancer; ZOLEDRONIC ACID; MULTIPLE-MYELOMA; RISK-FACTORS; BISPHOSPHONATES; BONE; RECOMMENDATIONS; PREVENTION; BREAST;

D O I：

10.1080/07357900802208608

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ONJ is an important toxicity in cancer patients receiving bisphosphonate therapy. Here we report a higher than usual incidence of ONJ, 11 of 60 (18.3%, 95% Confidence Interval, CI: 9%-28%) patients enrolled in a phase II clinical trial combining bevacizumab, docetaxel, thalidomide, and prednisone (ATTP) in chemotherapy-naive men with metastatic castration resistant prostate cancer (mCRPC). The use of bisphosphonates was allowed at study entry. Our study suggests that anti-angiogenic and chemotherapy agents can predispose to the development of ONJ in men with mCRPC on zoledronic acid. Imaging modalities, such as bone scans, may be useful in following the clinical course of patients who develop ONJ.

引用

页码：221 / 226

页数：6

共 33 条

[1] Guidance on the use of bisphosphonates in solid tumours:: recommendations of an international expert panel [J].

Aapro, M. ;

Abrahamsson, P. A. ;

Body, J. J. ;

Coleman, R. E. ;

Colomer, R. ;

Costa, L. ;

Crino, L. ;

Dirix, L. ;

Gnant, M. ;

Gralow, J. ;

Hadji, P. ;

Hortobagyi, G. N. ;

Jonat, W. ;

Lipton, A. ;

Monnier, A. ;

Paterson, A. H. G. ;

Rizzoli, R. ;

Saad, F. ;

Thuerlimann, B. .

ANNALS OF ONCOLOGY, 2008, 19 (03) :420-432

[2]

Bagan Jose, 2007, Med Oral Patol Oral Cir Bucal, V12, pE336

[3] Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].

Bamias, A ;

Kastritis, E ;

Bamia, C ;

Moulopoulos, LA ;

Melakopoulos, L ;

Bozas, G ;

Koutsoukou, V ;

Gika, D ;

Anagnostopoulos, A ;

Papadimitriou, C ;

Terpos, E ;

Dimopoulos, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587

[4]

Burr D. B., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P354

[5] Osteonecrosis of the jaw.: A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates.: Report of five cases and review of the literature [J].

Cavanna, Luigi ;

Berte, Raffaella ;

Arcari, Annalisa ;

Mordenti, Patrizia ;

Pagani, Raffaella ;

Vallisa, Daniele .

EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2007, 18 (05) :417-422

[6] Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws [J].

Chiandussi, S. ;

Biasotto, M. ;

Dore, F. ;

Cavalli, F. ;

Cova, M. A. ;

Di Lenarda, R. .

DENTOMAXILLOFACIAL RADIOLOGY, 2006, 35 (04) :236-243

[7]

Durie BGM, 2005, NEW ENGL J MED, V353, P99

[8]

Estilo CL., 2004, J CLIN ONCOLPROC AM, V22, P8088

[9] Zoledronic acid and angiogenesis [J].

Ferretti, Gianluigi ;

Fabi, Alessandra ;

Carlini, Paolo ;

Papaldo, Paola ;

Felici, Alessandra ;

Tornao, Silverio ;

Cognetti, Francesco .

CLINICAL CANCER RESEARCH, 2007, 13 (22) :6850-6850

[10]

Fournier P, 2002, CANCER RES, V62, P6538

← 1 2 3 4 →